CA-PSMF
3.5.2022 14:02:31 CEST | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient deaths by 2030, announced the winners of its 2021 Humanitarian and Lewis Blackman awards at its 8th annual World Patient Safety, Science & Technology Summit (WPSSTS). President Bill Clinton, the 42nd President of the United States, was recognized with the Joe Kiani Humanitarian award, Javier Davila received the Beau Biden Humanitarian award and Jannicke Mellin-Olson was honored with the Steven Moreau Humanitarian award. The 2nd annual Lewis Blackman award was presented to Ingrid Bonilla.
“Achieving our mission of zero preventable patient deaths by 2030 relies on individuals coming together to create change,” said Michael Ramsay, MD, CEO of Patient Safety Movement Foundation. “We are proud to recognize all four of this year’s winners for their individual efforts, leadership and commitment to improving patient safety globally.”
The Humanitarian Awards recognize leaders who have made significant progress in the last year eliminating or raising awareness of preventable patient deaths. This year, recipients were honored across three categories – the Joe Kiani award, Beau Biden award and Steven Moreau award. The Joe Kiani award was named after the founder of the Patient Safety Movement Foundation and recognizes individuals who are committed to the foundation’s mission. The Beau Biden award was created in 2018 to honor Beau Biden, former attorney general of Delaware, member of the Army National Guard and late son of President Joe Biden, for his devotion to public service and the safety of others, especially children. The Steven Moreau award is presented annually to a hospital administrator who possesses a zeal for improving patient safety at their hospital. This year’s recipients included:
- President Bill Clinton , 42nd President of the United States, has been a long-standing supporter of patient safety. During his time in office, he was committed to expanding access to affordable, quality health care for all Americans. He received the first-ever Joe Kiani award for his continued support of the Patient Safety Movement Foundation and its goal to reach zero preventable medical deaths by 2030.
- Javier Davila , PSMF ambassador in Mexico, former medical director at the Mexican Social Security Institute and head of medical education, research and health public policy, was recognized with the Beau Biden award for his passion for public service and improving patient safety for others. Since joining PSMF, he has focused on promoting the culture of safety in Mexico and has helped build affiliations with many prestigious public and private hospitals, as well as establish relationships with numerous organizations to help further the mission.
- Jannicke Mellin-Olson , MD, DPH, has been a longtime patient safety advocate. Her passion for patient safety started during her residency at Trondheim University Hospital in Norway, where she worked on a number of patient safety initiatives. She received the Steven Moreau award for her continued efforts to spread the mission to stakeholders across Europe, as well as in her current clinical post at Baerum Hospital in Oslo, Norway.
The Lewis Blackman Leadership Award was established in 2020 to recognize active students or residents pursuing a career in healthcare who demonstrate exemplary leadership skills in patient safety that contribute to PSMF’s vision of eliminating preventable medical harm. It was designed in honor of Lewis Blackman, who died on November 6, 2000 at the age of 15, as a result of preventable medical harm in a healthcare setting with a poor culture of safety and inadequate training. Before his death, he was an outstanding student and his mother, Helen Haskell, has become an advocate for improving patient safety, especially through education.
- Ingrid Bonilla , fourth year medical student at Medical University of South Carolina, has demonstrated an early commitment and passion for improving patient safety. During her time in medical school, she has worked with noted patient safety champions in South Carolina on new criteria to prevent central line infections, collected data on COVID-19 to determine how it presents itself in children and how they should be treated and has also focused on improving communication between patients, families and providers.
The Patient Safety Movement Foundation launched the Humanitarian Awards in 2013 to recognize individuals whose work helps advance patient safety and the Lewis Blackman Award was created in 2019. To learn more about the awards and past winners, visit: https://patient.sm/LewisBlackman .
The full WPSSTS event is available to watch on demand for $20 through May 9, 2022 at: http://patient.sm/summit2022 or free after May 9 at: http://patient.sm/summitYT .
About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005501/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
